Novel myostatin antagonist peptides to enhance muscle function.

Patricio Sepulveda
Myostin Therapeutics Pty Ltd

27th October 2012

The proposal was to develop peptide inhibitors of the myostatin-signaling pathway, with the long-term goal of performing trials in Duchenne muscular dystrophy (DMD). Inhibiting the myostatin signaling pathway has the potential to improve muscle regeneration, decrease fibrosis, and increase muscle mass and strength in DMD as well as in a number of other muscle wasting and dystrophic conditions. While TACT acknowledged the benefits of this general therapeutic approach, Myostin is still selecting a lead compound, and additional data are required before the clinical impact of their therapeutic approach can be assessed.

12 Apr 2017